Revolutions Medical CORP POS AM, filed Dec 14, 2011: IDEA: XBRL DOCUMENT
|
ACQUISITION OF CLEAR IMAGE ACQUISITION CORP
|
12 Months Ended |
|---|---|
|
Dec. 31, 2010
|
|
| ACQUISITION OF CLEAR IMAGE ACQUISITION CORP |
NOTE 9 - ACQUISITION OF CLEAR IMAGE ACQUISITION CORP
In
December 2008, the Company acquired the minority interest of Clear
Image Acquisition Corporation (“Acquisition Corp”). The
Company had previously acquired 62.2% of Acquisition Corp as part
of the acquisition of Clear Image, Inc. (“Clear Image”)
in March 2007. The purchase price for the remaining minority
interest of Acquisition Corp, excluding transaction costs, included
a stock payment of 12,208 shares at closing.
On
March 26, 2007, the Company completed the acquisition of Clear
Image Acquisition Corporation (“Acquisition Corp.”) in
exchange for 8,273,788 shares of RevMed common stock. Acquisition
Corp is a company that was formed by certain shareholders of Clear
Image, Inc. (“Clear Image”) in order to assemble a
control block of the shares of Clear Image for the purposes of such
a transaction. The sole asset of Acquisition Corp was a block of
8,260,139 shares of the Common Stock of Clear Image, a development
stage company which is developing certain proprietary and patent
pending technology related to color MRI scans. The block of Clear
Image shares owned by Acquisition Corp represented 62.2% of Clear
Image’s outstanding common stock. By acquiring Acquisition
Corp, RevMed has acquired control of Clear Image, Inc. as a
partially-owned subsidiary.
In
determining the number of shares to be exchanged by RevMed for the
shares of Clear Image shares held by Acquisition Corp., the Board
based the transaction value on the funds expended by Clear Image
for the color MRI technology in its then current state, using a
value of Forty Cents ($.40) per share, which was the average market
value when the acquisition agreement was signed in January, 2007.
During the third quarter of 2007, it was determined that the
accounting treatment for the transaction should be accounted for in
accordance with FASB Interpretation No. 4. “Applicability of
FASB Statement No.2 to Business Combinations Accounted for by the
Purchase Method” and Statement of Financial Accounting
Standards No. 2 “Accounting for Research and Development
Costs.” which require research and development costs to be
expensed if there are no alternative uses. Accordingly, the Company
recorded goodwill of $23,274 and an expense of
$3,309,515.
The
shareholders of Acquisition Corp. did not receive a larger portion
of the voting rights in RevMed, the surviving company, because of
RevMed’s outstanding preferred stock (See Note 5.
“Preferred Stock and Common Stock Transactions”), so
the transaction did not require the use of recapitalization or
reverse merger accounting. RevMed plans to pay the minimal costs of
Acquisition Corp’s liquidation and dissolution.
Prior
to RevMed’s acquisition of Acquisition Corp., RevMed’s
officer and directors were directors and shareholders of Clear
Image, Inc. and, along with other shareholders, contributed their
Clear Image shares to Acquisition Corp. In connection with
RevMed’s acquisition of Acquisition Corp., Ron Wheet,
RevMed’s CEO and a Director, received 2,286,000 shares of
RevMed restricted common stock;Dr. Beahm, a Director, received
1,599,125 shares of RevMed restricted common stock; and Mr.
O’Brien, a Director, received 1,645,625 shares of RevMed
restricted common stock.
|